• Nxera Pharma settled a UK patent infringement case over its miniG platform technology with OMass Therapeutics.
• The deal resolves High Court proceedings covering alleged past infringement of two granted patents tied to the miniG platform.
• Settlement terms remain confidential between the parties.
• Nxera flagged continued monitoring of unauthorized use of its NxWave GPCR drug-discovery technologies, with enforcement action where needed.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nxera Pharma Co. Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610010627PRIMZONEFULLFEED1001275737) on October 01, 2026, and is solely responsible for the information contained therein.